At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 135 enrolled
Drug / intervention
cTIVbiological
Likely dose
cTIV 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture, Using the Strain Composition 2007/2008, When Administered to Adult and Elderly Subjects
In Brief
A Phase 3 clinical trial evaluating cTIV for Seasonal Influenza Vaccine. Completed, enrolled 135 participants across 2 sites.
Detailed Summary
Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell culture, using the strain composition 2007/2008, when administered to adult and elderly subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza Vaccine
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
Primary CompletionAug 2007
First PostedAug 2007
TodayJul 2026
First PostedAug 6, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.9 years ago
Interventions
cTIVbiological
One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle